Pacira BioSciences, Inc.

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
21.37 ^USD	+0.33%		+1.96%	-36.66%

Jul. 10	Pacira BioSciences, Inc. Announces Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025	CI
Jul. 09	RBC Cuts Price Target on Pacira BioSciences to $42 From $45, Keeps Outperform Rating	MT

Pacira BioSciences, Inc. Reports Preliminary Unaudited Revenue Results for 2020

January 07, 2021 at 07:30 am EST

Pacira BioSciences, Inc. reported preliminary unaudited revenue results for 2020. For the year, the company reported net revenue of $429.6 million, a 2.0% increase compared with net revenue of $421.0 million reported for 2019.

Latest news about Pacira BioSciences, Inc.

Pacira BioSciences, Inc. Announces Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025	Jul. 10	CI
RBC Cuts Price Target on Pacira BioSciences to $42 From $45, Keeps Outperform Rating	Jul. 09	MT
Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38	Jul. 03	MT
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic	Jul. 02	DJ
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2500 Value Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 3000 Value Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2000 Value Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2000 Value-Defensive Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 3000E Value Index	Jun. 30	CI
Transcript : Pacira BioSciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM	May. 14
Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering	May. 10	MT
Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating	May. 08	MT
Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Pacira BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q1 Revenue $167.1M, vs. Street Est of $165.7M	May. 07	MT
Pacira BioSciences, Inc. announces an Equity Buyback for $150 million worth of its shares.	May. 07	CI
Pacira Biosciences, Inc. Reiterates Earnings Guidance for the Full Year 2024	May. 07	CI
Pacira BioSciences, Inc. authorizes a Buyback Plan.	May. 06	CI
Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	Mar. 13
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	Mar. 13	MT
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	Mar. 13	DJ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	Mar. 13	CI
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	Mar. 08	MT
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating	Mar. 01	MT

Chart Pacira BioSciences, Inc.

Duration

Period

More charts

Company Profile

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Pacira BioSciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.37 USD

Average target price

41.78 USD

Spread / Average Target

+95.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PACIRA BIOSCIENCES, INC.	-36.66%	991M
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B

Other Pharmaceuticals